Table 3. Association of clinical and pathologic parameters with Cleason score (GS) group: upgrading from biopsy GS 5–6 to GS >6 at radical prostatectomy.
| Variables | Upgrade (n= 1841) | No upgrade (n = 3230) | p value |
|---|---|---|---|
| Age, yr | |||
| Median (range) | 59.0 (36.0–77.0) | 57.0 (34.0–79.0) | |
| Mean (SD) | 58.7 (6.4) | 57.0 (6.5) | <0.0001 |
| PSA, ng/ml | |||
| Median (range) | 5.1 (0.5–97.2) | 4.5 (0.2–43.1) | |
| Mean (SD) | 6.1 (4.4) | 5.0 (3.1) | <0.0001 |
| No. of positive cores | |||
| Median (range) | 2.0 (1.0–12.0) | 2.0 (1.0–12.0) | |
| Mean (SD) | 3.0 (2.2) | 2.4 (1.8) | <0.0001 |
| Maximum % cancer/core | |||
| Median (range) | 40.0 (1.0–100.0) | 25.0 (1.0–100.0) | |
| Mean (SD) | 43.6 (29.2) | 33.7 (26.7) | <0.0001 |
| Pathology weight (continuous) | |||
| Median (range) | 47.3 (11.7–198) | 50.7 (12.2–254.0) | |
| Mean (SD) | 50.4 (16.6) | 55.9 (22.0) | <0.0001 |
| Pathology weight (%) | |||
| ≤25 g | 20 (43.5) | 26 (56.5) | |
| 26–50 g | 967 (42.4) | 1313 (57.6) | <0.0001 |
| 51–75 g | 597 (37.3) | 1005 (62.7) | |
| ≥75 g | 257 (22.5) | 886 (77.5) | |
| Clinical stage (%) | |||
| ≤T1c | 1110 (29.4) | 3667 (70.6) | |
| T2a | 240 (23.5) | 779 (76.5) | 0.006 |
| ≥T2b | 105 (30.9) | 235 (69.1) | |
SD = standard deviation; PSA= prostate-specific antigen.